Rasitrio (Novartis) combination is EU approved for Hypertension

Rasitrio, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide in a single pill from Novartis has received approval from the European Commission for the treatment of high blood pressure. The pivotal study supporting the application showed that Rasitrio produced statistically significant blood pressure reductions compared to dual combinations of each of its individual components, including aliskiren/amlodipine 300 mg/10 mg, aliskiren/HCTZ 300 mg/25 mg and amlodipine/HCTZ 10 mg/25 mg. The effect of Rasitrio was observed as early as one week after initiation of therapy and was maintained over the entire 24-hour dose interval. This combination is approved in the USA as Amturnide.